Study of Ataluren (PTC124®) in Cystic Fibrosis

Official Title: An Open-Label Safety and Efficacy Study for Patients With Nonsense Mutation Cystic Fibrosis Previously Treated With Ataluren (PTC124®)

This is a Phase 3, multicenter, open-label, safety and efficacy study of ataluren in patients with nonsense mutation cystic fibrosis who participated in the previous Phase 3 study with ataluren (PTC124-GD-009-CF; Study 009).

NCT02107859
McColley, Susanna, MD
Interventional
No

Contact Information:

Naiomi Nemoto

Clinical Research Coordinator

312.227.6266